• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » David Ho

David Ho

Articles

ARTICLES

Singapore's A*STAR draws pharma, academia to boost manufacturing innovations

Oct. 31, 2018
By David Ho
HONG KONG – Singapore's Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) aimed at bringing together the city-state's public sector research capabilities and major global players in the pharma industry to transform the manufacturing operations and technologies of the industry for greater efficiencies.
Read More

Singapore's A*STAR draws pharma, academia to boost manufacturing innovations

Oct. 30, 2018
By David Ho
HONG KONG – Singapore's Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) aimed at bringing together the city-state's public sector research capabilities and major global players in the pharma industry to transform the manufacturing operations and technologies of the industry for greater efficiencies.
Read More

Maz offers ostrich antibody IP in A*STAR collaboration targeting dengue viruses

Oct. 24, 2018
By David Ho
HONG KONG – Biotech company Maz World Ltd. is working with the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research (IMCB A*STAR) to use its ostrich antibody technology to neutralize the four serotypes of dengue viruses.
Read More

Maz offers ostrich antibody IP in A*STAR collaboration targeting dengue viruses

Oct. 23, 2018
By David Ho
HONG KONG – Biotech company Maz World Ltd. is working with the Institute of Molecular and Cell Biology of Singapore's Agency for Science, Technology and Research (IMCB A*STAR) to use its ostrich antibody technology to neutralize the four serotypes of dengue viruses.
Read More

Standards being introduced to 1,000+ med devices as price caps cause disputes in India

Oct. 11, 2018
By David Ho

Xact wins CE mark, $5M funding for its percutaneous robotics navigation system

Sep. 25, 2018
By David Ho

J&J's Depuy in hot water over faulty hip implants in India

Sep. 20, 2018
By David Ho

U.S.-Israel collaboration results in Vitalminer novel monitoring tech

Sep. 18, 2018
By David Ho

Indian rupee depreciation is a good news, bad news scenario for drugmakers

Sep. 12, 2018
By Alex Ho and David Ho
HONG KONG – Some outward-looking Indian drugmakers may be benefiting from the cheapest rupee ever, but others, which hedged their currency bets, could take a hit.
Read More

Indian rupee depreciation is a good news, bad news scenario for drugmakers

Sep. 10, 2018
By Alex Ho and David Ho
HONG KONG – Some outward-looking Indian drugmakers may be benefiting from the cheapest rupee ever, but others, which hedged their currency bets, could take a hit.
Read More
View All Articles by David Ho

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe